Combined NK1 antagonism and serotonin reuptake inhibition: Effects on emotional processing in humans

Journal of Psychopharmacology

Volumn 27, Issue 5, 2013, Pages 435-443

  Harmer, Catherine J ^a   Dawson, Gerry R ^b   Dourish, Colin T ^b   Favaron, Elisa ^a   Parsons, Elizabeth ^c   Fiore, Monica ^c   Zucchetto, Mauro ^c   Bifone, Angelo ^c   Poggesi, Italo ^c   Fernandes, Sofia ^c   Alexander, Robert C ^c   Goodwin, Guy M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GSK   (Italy)

Author keywords

Antidepressants; biomarker models; depression; emotional processing; NK1 receptors; serotonin

Indexed keywords

CITALOPRAM; DRUG METABOLITE; GSK 419301; GSK 424887; N [1 (3 CHLORO 1 NAPHTHALENYL)ETHYL] 2 [4 (4 FLUOROPHENYL) 1 METHYL 4 PIPERIDINYL] N METHYLACETAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ADULT; ARTICLE; ATTENTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; EMOTION; EMOTIONAL PROCESSING; FACIAL EXPRESSION; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; MENTAL FUNCTION; MENTAL TASK; NORMAL HUMAN; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOGNITION; STARTLE REFLEX;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DOUBLE-BLIND METHOD; EMOTIONS; FACIAL EXPRESSION; HUMANS; MALE; MEMORY; NEUROKININ-1 RECEPTOR ANTAGONISTS; PERCEPTION; PIPERIDINES; RECOGNITION (PSYCHOLOGY); SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84876520102     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112472558     Document Type: Article

References (44)

1. Al-Ghazawi M, Tutunji M, Mohsen M, et al. Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. Int J Clin Pharmacol Therapeut. 2007 ; 45: 300-306
2. Anderson NH. Likableness ratings of 555 personality trait words. J Pers Soc Psychol. 1968 ; 9: 272-279
3. Arnone D, Horder J, Cowen PJ, et al. Early effects of mirtazapine on emotional processing. Psychopharmacology (Berl). 2009 ; 203: 685-691
4. Beck AT, Rush AJ, Shaw BF, et al Cognitive Therapy of Depression. New York: Guildford Press ; 1979 :
5. Blair RJ, Curran HV. Selective impairment in the recognition of anger induced by diazepam. Psychopharmacology (Berl). 1999 ; 147: 335-338
6. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Psychol. 1974 ; 47: 211-218
7. Browning M, Reid C, Cowen PJ, et al. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol. 2007 ; 21: 684-690
8. Chandra P, Hafizi S, Massey-Chase R, et al. NK1 receptor antagonism and emotional processing in healthy volunteers. J Psychopharmacol. 2010 ; 24: 481-487
9. Chenu F, Guiard BP, Bourin M, et al. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res. 2006 ; 172: 256-263
10. Dawson GR, Goodwin G. Experimental medicine in psychiatry. J Psychopharmacol. 2005 ; 19: 565-566
11. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006 ; 31: 251-272
12. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des. 2009 ; 15: 1647-1674
13. Ekman P, Friesen WV Pictures of Facial Affect. Palo Alto, CA: Consulting Psychologists Press ; 1976 :
14. Eysenck SBG, Eysenck HJ, Barrett P. A revised version of the psychoticism scale. Pers Individual Differences. 1985 ; 6: 21-29
15. Grillon C, Levenson J, Pine DS. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology. 2007 ; 32: 225-231
16. Guiard BP, Przybylski C, Guilloux JP, et al. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem. 2004 ; 89: 54-63
17. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. 2002 ; 63: S18 - S24
18. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002 ; 297: 400-403
19. Harmer CJ, Bhagwagar Z, Perrett DI, et al. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003a ; 28: 148-152
20. Harmer CJ, Cowen PJ, Goodwin GM. Efficacy markers in depression. J Psychopharmacol. 2011 ; 25: 1148-1158
21. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009a ; 195: 102-108
22. Harmer CJ, Heinzen J, O'Sullivan U, et al. Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers. Psychopharmacology (Berl). 2008 ; 199: 495-502
23. Harmer CJ, Hill SA, Taylor MJ, et al. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry. 2003b ; 160: 990-992
24. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009b ; 166: 1178-1184
25. Harmer CJ, Shelley NC, Cowen PJ, et al. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004 ; 161: 1256-1263
26. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 ; 59: 216-223
27. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998 ; 281: 1640-1645
28. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004 ; 29: 385-392
29. Lang PJ, Bradley MM, Cuthbert BN International affective picture system (IAPS): Technical manual and affective ratings. Gainesville, FL: University of Florida, Center for Research in Psychophysiology ; 1999 :
30. MacLeod C, Mathews A, Tata P. Attentional bias in emotional disorders. J Abnorm Psychology. 1986 ; 95: 15-20
31. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatry. 2001 ; 158: 1843-1849
32. Mogg K, Bradley BP. A cognitive-motivational analysis of anxiety. Behav Res Ther. 1998 ; 36: 809-848
33. Murphy SE, Downham C, Cowen PJ, et al. Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology (Berl). 2008 ; 199: 503-513
34. Murphy SE, Norbury R, O'Sullivan U, et al. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009 ; 194: 535-540
35. Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol. 2002 ; 17: S1 - S12
36. Phan KL, Wager T, Taylor SF, et al. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage. 2002 ; 16: 331-348
37. Pringle A, Browning M, Cowen PJ, et al. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1586-1592
38. Roiser JP, Elliott R, Sahakian BJ. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012 ; 37: 117-136
39. Tranter R, Bell D, Gutting P, et al. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord. 2009 ; 118: 87-93
40. Von Zerssen D, Strian F, Schwarz D Psychological Measurements in Psychopharmacology. Pichot P, ed. Basel, Switzerland: Karger ; 1974: 189-202.
41. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the Positive and Negative Affect Schedule scales. J Pers Soc Psychol. 1988 ; 54: 1063-1070
42. Young AW, Rowland D, Calder AJ, et al. Facial expression megamix: Tests of dimensional and category accounts of emotion recognition. Cognition. 1997 ; 63: 271-313
43. Zangara A, Blair RJ, Curran HV. A comparison of the effects of a beta-adrenergic blocker and a benzodiazepine upon the recognition of human facial expressions. Psychopharmacology (Berl). 2002 ; 163: 36-41
44. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983 ; 67: 361-370